7/23/2019 Onco Management
1/78
PRINCIPLES OF ONCOLOGY ANDOUTLINE OF MANAGEMENT
7/23/2019 Onco Management
2/78
ONCOLOGY
The name itself comes to us thou!h Gee"an# Latin $o#s fo a ca%& fom the Gee"karkinosto the Latin cance& an# efes tothe cla$'li"e %loo# (essels e)ten#in! o(e
the suface of an a#(ance# %east cance*
Ru#olf +icho$ has the ce#it fo %ein! the,st to #emonstate that cance is a
#isease of cells an# that the #isease-o!esse# as a esult of a%nomal-olifeation*
7/23/2019 Onco Management
3/78
Causes of cance
Causes
Genetics
Mutationsof !enes
En(ionmental
To%acco
Alcohol
U+e)-osue
Ra#iation
Infections
O%esit.
7/23/2019 Onco Management
4/78
Genetics
Genes Tumours Syndrome
/RCA 01 /RCA 2 /east & o(a. & colon 3ee#ita. %easto(aian cance
APC Intestinal a#enomas &colon cance
FAP
/CL'0&/CL'2 Mantle cell l.m-homa
E4T 0&E4T 2 Follicula l.m-homa
3PC 0 Chon#osacoma
R/ 0 Retino%lastoma 3ee#ia.
etino%lastomaRET Me#ulla. ca th.oi# &
-heochomoc.tomaMen 2
MEN 0 Paath.oi#&-anceas&-ituata.
MEN 0
MET Pa-illa. enal tumou
7/23/2019 Onco Management
5/78
Essentials of cance!o$th
7/23/2019 Onco Management
6/78
Malignant transformation
Establish an autonomous lineageResist signals that inhibit growth
Acquire independence from signalsstimulating growth
Obtain immortality
Evade apoptosis
Acquire angiogenic competence
Acquire the ability to invade
Acquire the ability to disseminate and implant
Evade detectioneliminationGenomic instability
Subvert communication to and from theenvironmentmilieu
7/23/2019 Onco Management
7/78
Pinci-les of oncolo!.mana!ement
!" #re$referral mechanismsPatient e#ucation to eco!nise #an!es.m-toms an# si!ns
Self e)amination %. the -atient* e*!* %east& testis
E#ucation& !ui#ance an# -ost'efeal fee#%ac" fo famil.-actitiones in eco!nisin! #an!e s.m-toms an# si!ns an#eassuance*
A--o-iate efeal to s-ecialists hel-e# %. -ofomas containin!in#ications to efe sus-ecte# s"in& coloectal& %east& hea# an#nec" an# u--e !astointestinal cance
Rea#. a(aila%ilit. of eal. assessment an# #ia!nostic tests
%" #rimary diagnosis after referral'clinical assessment -lus
in(esti!ations& e*!* ima!in!& en#osco-.& %io-s.& ,ne nee#leas-iation c.tolo!.& la-aosco-.
&" Staging'a##itional in(esti!ation to seach fo e)tent of s-ea#5
Local s-ea#
L.m-h no#e s-ea# 3aemato!enous s-ea# 6%one& lun!& li(e& %ain7
7/23/2019 Onco Management
8/78
'" Multidisciplinary decision ma(ing'to fomulate the aims ofteatment an# to #eci#e the o-timum teatment5 Teatment -lannin!an# timin! of teatment& i#eall. %ase# on an#omise# contolle# tials6RCTs7 %ut also on e)-eience
Teatment ma. in(ol(e a sin!le entit.& o com%inations of su!e.&neoa#9u(ant o a#9u(ant chemothea-. an#8o a#iothea-.&-osto-eati(e chemo' o a#iothea-.& homonal thea-.
Patients shoul# %e entee# into clinical tials $hee %est teatment isnot esta%lishe#
)" The treatment
*" Repeat staging after operation or other treatment'$ith"no$le#!e of the o-eati(e ,n#in!s an# a e(ie$ of the histolo!.* Thisma. chan!e the -osto-eati(e -lan fo a#9u(ant thea-. an# -o(i#einfomation to calculate the statistical li"elihoo# of su(i(al8cue
+" #ost treatment surveillance'fo ecuence o a--eaance of ne$tumousin the ,el#*
," Auditof local outcomes to im-o(e :ualit. of cae* Patici-ation innational au#its
7/23/2019 Onco Management
9/78
Mana!ement
Sceenin!Dia!nose
Classif.
In(esti!ations
Sta!in! of cance
Teatment
7/23/2019 Onco Management
10/78
Sceenin!
Eal. #etection is the "e. to success in cance thea-.*
Sceenin! in(ol(es the #etection of #isease in anas.m-tomatic -o-ulation in o#e to im-o(e outcomes%. eal. #ia!nosis*
Sceenin! fo common cances usin! elati(el.nonin(asi(e tests is e)-ecte# to lea# to eal. #ia!nosis&allo$ moe conse(ati(e su!ical thea-ies $ith#ecease# mo%i#it.& an# -otentiall. im-o(e su!ical
cue ates an# o(eall su(i(al ates*
;e. factos that in
7/23/2019 Onco Management
11/78
Citeia fo sceenin!
The disease
> Reco!ni?a%le eal. sta!e
> Teatment at an eal. sta!e moe e=ecti(e than at a late sta!e
> Su@cientl. common to $aant sceenin!
The test
> Sensiti(e an# s-eci,c
> Acce-ta%le to the sceene# -o-ulation
> Safe
> Ine)-ensi(e
The programme
> A#e:uate #ia!nostic facilities fo those $ith a -ositi(e test
> 3i!h':ualit. teatment fo sceen'#etecte# #isease to minimise mo%i#it. an#motalit.
> Sceenin! e-eate# at inte(als if the #isease is of insi#ious onset
> /ene,t must out$ei!h -h.sical an# -s.cholo!ical ham
7/23/2019 Onco Management
12/78
Sceenin! use# in 5
Cance Sceenin! metho#s 5
/east Self e)amination & clinical e)amination &mammo!a-h.
Coloectal Fecal occult %loo# test 6FO/T7 o fecal
immunochemical test 6FIT7 & Dou%le'contast%aium enema 6DC/E7 & Fle)i%le si!moi#osco-.& colonosco-.
Postate Di!ital ectal e)amination 6DRE7 an# -ostate's-eci,c anti!en 6PSA7 test
Ce(i) Pa- test
7/23/2019 Onco Management
13/78
Dia!nosis
The #e,niti(e #ia!nosis of soli# tumos usuall. is o%taine#%. -efomin! a %io-s.of the lesion*
/io-s. ,n#in!s #etemine the tumo histolo!. an# !a#ean# thus assist in #e,niti(e thea-eutic -lannin!*
/io-s. s-ecimens of mucosal lesions usuall. ae o%taine#en#osco-icall. 6e*!*& (ia colonosco-e& %onchosco-e& oc.stosco-e7*
Lesions that ae easil. -al-a%le& such as those of the s"in&can eithe %e e)cise# o sam-le# %. -unch %io-s.*
Dee-'seate# lesions can %e locali?e# $ith com-ute#tomo!a-hic 6CT7 scan o ultasoun# !ui#ance fo %io-s.*
7/23/2019 Onco Management
14/78
O-en %io-sies ha(e the a#(anta!e of -o(i#in! moe tissue fo histolo!ice(aluationan# the #isa#(anta!e of %ein! an o-eati(e -oce#ue*
E)cisional %io-sies ae -efome# fo lesions fo $hich eithe coe %io-s.
is not -ossi%le o the esults ae non#ia!nostic*
E)cisional %io-sies shoul# %e -efome# $ith cuati(e intent& that is& %.o%tainin! a#e:uate tissue aoun# the lesion to ensue ne!ati(e su!icalma!ins*
Ma"in! of the oientation of the ma!ins %. sutues o cli-s %. thesu!eon an# in"in! of the s-ecimen ma!ins %. the -atholo!ist $ill allo$fo #etemination of the su!ical ma!ins an# $ill !ui#e su!ical e'e)cision if one o moe of the ma!ins ae -ositi(e fo micosco-ic tumoo ae close*
The %io-s. incision shoul# #iectl. o(elie the aea to %e emo(e# athethan tunnelin! fom anothe site& $hich uns the is" of contaminatin! ala!e ,el#*
Finall.& meticulous hemostasis #uin! a %io-s. is essential& %ecause ahematoma can lea# to contamination of the tissue -lanes an# can ma"esu%se:uent follo$'u- $ith -h.sical e)aminations much moe challen!in!*
7/23/2019 Onco Management
15/78
Classi,cation Di=eent tumous ae classi,e# in #i=eent $a.s
Most s:uamous e-ithelial tumous ae sim-l. classe# as $ell 6G07&mo#eate 6G27 o -ool. 6G7 #i=eentiate# *
A#enocacinomas ae also often classi,e# as G0& 2 o &
/ut -ostate cance is an e)ce-tion $ith $i#es-ea# use of the
Gleason s.stem* The Gleason s.stem !a#es -ostate canceacco#in! to the #e!ee of #i=eentiation of the t$o most -e(alentachitectual -attens*
The ,nal scoe is the sum of the t$o !a#es an# can (a. fom 2 60B 07 to 0 6 B 7& $ith the hi!he scoes in#icatin! -ooe-o!nosis*
The mana!ement of mali!nant l.m-homas is %ase# ,ml. u-onhisto-atholo!icalclassi,cation5 the ,st #istinction is %et$een3o#!"ins l.m-homa 63L7 an# the non'3o#!"ins l.m-homa 6N3L7*Each of these main t.-es of l.m-homa is then su%classi,e#acco#in! to a #i=eent scheme*
The ol# 3ealth O!ani?ation8Re(ise# Euo-eanAmeicanl.m-homa 63O8REAL7 s.stem classi,es 3o#!"ins l.m-homa into
7/23/2019 Onco Management
16/78
In(esti!ations
Ima!in! mo#alitiesMa"es
7/23/2019 Onco Management
17/78
Tumou ma"es
Po!nostic an# Pe#icti(e Tissue Ma"es
Tumo ma"es ae su%stances that can %e #etecte# inhi!he than nomal amounts in the seum& uine& otissues of -atients $ith cetain t.-es of cance*
Tumos ma"es ae -o#uce# eithe %. the cance cellsthemsel(es o %. the %o#. in a es-onse to the cance*
The temprognostic marker!eneall. is use# to #esci%e
molecula ma"es that -e#ict #isease'fee su(i(alisease's-eci,c su(i(al& an# o(eall su(i(al&
heeas the tempredictive markeroften is use# in theconte)t of -e#ictin! es-onse to cetain thea-ies*
7/23/2019 Onco Management
18/78
Seum ma"es
Postate s-eci,c anti!enCacinoem%.onic anti!en
Al-ha feto -otein
CA 0'
CA 2J'2
7/23/2019 Onco Management
19/78
PSA Postate's-eci,c anti!en 6PSA7 is -otentiall. the %est seum
ma"e no$ a(aila%le*
PSA is an an#o!en'e!ulate# seine -otease -o#uce# %. the-ostate e-ithelium*
PSA le(els ma. %e ele(ate# in the %loo# of men $ith %eni!n-ostate con#itions such as -ostatitis an# %eni!n -ostatich.-e-lasia& as $ell as in men $ith -ostate cance*
PSA le(els ha(e %een sho$n to %e useful in e(aluatin! thee=ecti(eness of -ostate cance teatment an# monitoin! foecuence afte thea-.*
In monitoin! fo ecuence& a ten# of inceasin! le(els isconsi#ee# moe si!ni,cant than a sin!le a%solute ele(ate#(alue*
A total seum PSA le(el of K n!8mL shoul# %e use# as atheshol# fo -efomin! a -ostate %io-s.
7/23/2019 Onco Management
20/78
CEA
Cacinoem%.onic anti!en 6CEA7 is a !l.co-otein foun# in theem%.onic en#o#emal e-ithelium*
Ele(ate# CEA le(els ha(e %een #etecte# in -atients $ith -ima.coloectal cance as $ell as in -atients $ith %east& lun!& o(aian&-ostate& li(e& an# -anceatic cance*
Le(els of CEA also ma. %e ele(ate# in %eni!n con#itions such as#i(eticulitis& -e-tic ulce #isease& %onchitis& li(e a%scess& an#alcoholic cihosis& es-eciall. in smo"es an# in el#el. -esons*
CEA measuement is most commonl. use# in the mana!ement of
coloectal cance*
CEA le(els ma. %e useful if o%taine# -eo-eati(el. an#-osto-eati(el. in -atients $ith a #ia!nosis of coloectal cance*Peo-eati(e ele(ation of CEA le(el is an in#icato of -oo -o!nosis*
7/23/2019 Onco Management
21/78
AFP Al-ha'feto-otein 6AFP7 is a !l.co-otein nomall. -o#uce# %. a
#e(elo-in! fetus* AFP le(els #ecease soon afte %ith in health. a#ults*
An ele(ate# le(el of AFP su!!ests the -esence of eithe -ima. li(ecance o a !em cell tumo of the o(a. o testicle* Rael.& othe t.-esof cance such as !astic cance ae associate# $ith an ele(ate# AFP
le(el*
/eni!n con#itions that can cause ele(ations of AFP inclu#e cihosis&he-atic necosis& acute he-atitis& chonic acti(e he-atitis& ata)ia'telan!iectasia& is"ott'Al#ich s.n#ome& an# -e!nanc.*
The sensiti(it. of an ele(ate# AFP le(el fo #etectin! 3CC isa--o)imatel. * AFP is consi#ee# to %e sensiti(e an# s-eci,cenou!h to %e use# fo sceenin! fo 3CC in hi!h'is" -o-ulations*
Cuent consensus ecommen#ations ae to sceen health. he-atitis /
(ius caies $ith annual o semiannual measuement of AFP le(el an#to sceen caies $ith cihosis o chonic he-atitis an# -atients $ith
7/23/2019 Onco Management
22/78
CA 0'
Cance anti!en 0' 6CA 0'7 is atumo'elate# anti!en that $as oi!inall.#e,ne# %. a monoclonal anti%o#.-o#uce# %. a h.%i#oma -e-ae# fom
muine s-leen cells immuni?e# $ith ahuman coloectal cance cell line*
The #ata ae insu@cient to ecommen#use of CA 0' fo sceenin!& #ia!nosis&su(eillance& o monitoin! of thea-. focolon cance*
7/23/2019 Onco Management
23/78
CA 0'
Cance anti!en 0' 6CA 0'7 is an e-ito-e of a la!emem%ane !l.co-otein enco#e# %. the MUC1!ene thattumo cells she# into the %loo#steam*
The CA 0' e-ito-e is eco!ni?e# %. t$o monoclonalanti%o#ies in a san#$ich a#ioimmunoassa.*
CA 0' le(els ae most useful in follo$in! the couse ofteatment in $omen #ia!nose# $ith a#(ance# %east cance*CA 0' le(els ae infe:uentl. ele(ate# in eal. %east cance*
CA 0' le(els can %e incease# in %eni!n con#itions such aschonic he-atitis& tu%eculosis& sacoi#osis& -el(icin
7/23/2019 Onco Management
24/78
CA 2J'2
The MUC'0 !ene -o#uct in the seum ma. %e:uantitate# %. usin! a#ioimmunoassa. $ith amonoclonal anti%o#. a!ainst the cance anti!en2J'2 6CA 2J'27*
CA 2J'2 le(els can %e ele(ate# in %east canceas $ell as in cances of the colon& stomach&"i#ne.& lun!& o(a.& -anceas& uteus& an# li(e*
Fist'timeste -e!nanc.& en#ometiosis& %eni!n%east #isease& "i#ne. #isease& an# li(e #iseasealso ma. %e associate# $ith ele(ate# CA 2J'2le(els*
7/23/2019 Onco Management
25/78
Ciculatin! Tumo Cells Ciculatin! tumo cells 6CTCs7 ae cells -esent in the %loo# that
-ossess anti!enic o !enetic chaacteistics of a s-eci,c tumot.-e*
One CTC #etection metho#olo!. is ca-tue an# :uantitation of CTCs$ith immunoma!netic %ea#s coate# $ith anti%o#. s-eci,c fo cell'suface& e-ithelial& o cance anti!ens*
Anothe metho#olo!. use# to #etect cance cells in the -ei-heal%loo# is RT'PCR* It has %een su!!este# that measuement of CTCscan %e an e=ecti(e tool fo selectin! -atients $ho ha(e a hi!h is"of ela-se an# fo monitoin! e@cac. of cance thea-.*
CTCs ha(e -o%a%l. %een most e)tensi(el. stu#ie# in %east cance*The most -omisin! #ata come fom the use of CTC measues inmetastatic %east cance*
The -o!nostic im-lications of #etection of CTCs %. RT'PCR ha(e%een intensi(el. stu#ie# fo melanoma*
7/23/2019 Onco Management
26/78
In the ecent multicente Sun%elt Melanoma Tial&
seial RT'PCR $as -efome# on -ei-heal %loo#sam-les usin! fou ma"est.osinase& melanomaanti!en eactin! to T cell 6MART'07& melanoma
anti!en 6MAGE7& an# !- 0to #etect occultmelanoma cells in the %loo#steam*
Althou!h thee $ee no #i=eences in su(i(al%et$een -atients in $hom at least one ma"e $as
#etecte# an# those in $hom no ma"es $ee#etecte#& the #isease'fee su(i(al an# #istant
#isease'fee su(i(al $ee $ose fo -atients in$hom moe than one ma"e $as #etecte# at an.
time #uin! follo$'u-*
7/23/2019 Onco Management
27/78
RT PCR
7/23/2019 Onco Management
28/78
/one Mao$ Micometastases Micometastatic #isease in the %one mao$& also efee# to as
minimal residual disease,also is %ein! in(esti!ate# as a -otential-o!nostic ma"e*
/one mao$ micometastatic #isease usuall. is #etecte# %.stainin! %one mao$ as-iates $ith monoclonal anti%o#ies toc.to"eatin& %ut othe metho#olo!ies such as
7/23/2019 Onco Management
29/78
Immunohistochemist.-ell typesite of
origin.
Site of origincell
type.
#rognosis and
treatment.E-ithelial 6cacinoma75c.to"eatins
Postate5 -ostate's-eci,c anti!en 6PSA7
/east cacinoma5ece-tos 6ER& PR& 3ER27
L.m-hoi# 6l.m-homa75CD& CD2
Lun!5 th.oi#tansci-tion facto'0
6TTF'07
En#ocine tumous5 ;iJ-olifeati(e in#e)
Melanoc.tic6melanoma75 S0
Th.oi#5 th.o!lo%ulin GIST5 CD00J
Neuoen#ocine5 CD&
chomo!anin
Coloectum5 c.to"eatin
2 6C;27Stomach&!.naecolo!ical&
+ascula5 CD0& CDK lun!5 c.to"eatin J 6C;J7
M.oi#5 #esmin& actin Li(e5 3e-Pa
O(a.5 CA02
7/23/2019 Onco Management
30/78
Othe Ai#s
ELECTRON MICROSCOPY 5 Electonmicosco-. allo$s tissue to %e (isualise# at(e. hi!h ma!ni,cation& e*!* 0 to * It ma. hel- to #eci#e the linea!e of
a non'neo-lastic o neo-lastic cell in #i@cultcases*
PCR
CYTOGENETICS AND FIS3 Immunohistochemist. an# FIS3 ae use# toassess 3ER2 am-li,cation in %east cance*
7/23/2019 Onco Management
31/78
Clinical a--lications of PCR totissue sam-les
Mutational anal.sis
Clonalit.
Loss of heteo?.!osit.
Chomosomal a%nomalities
Detection of mico'o!anisms
7/23/2019 Onco Management
32/78
Sta!in!
The Intenational Union a!ainstCance 6UICC7 is es-onsi%le fothe TNM 6tumou& no#es&
metastases7 sta!in! s.stem focance*
This s.stem is com-ati%le $ith&
an# elates to& the AmeicanCance Societ. 6AQCC7 s.stem fosta!e !ou-in! of cance*
7/23/2019 Onco Management
33/78
Teatment
Su!icalMe#ical
Ra#iation
7/23/2019 Onco Management
34/78
Su!ical Mana!ement of Pima.Tumos
The !oal of su!ical thea-. fo cance is toachie(e oncolo!ic cue*
A cuati(e o-eation -esu--oses that the
tumo is con,ne# to the o!an of oi!in o tothe o!an an# the e!ional l.m-h no#e%asin*
The o-ea%ilit. of -ima. tumos is %est#etemine# %efoe su!e. $ith a--o-iateima!in! stu#ies that can #e,ne the e)tentof local'e!ional #isease*
7/23/2019 Onco Management
35/78
The unifom !oal fo all successful oncolo!ico-eations seems to %e achie(in! $i#el. ne!ati(ema!ins $ith no e(i#ence of macosco-ic o
micosco-ic tumo at the su!ical ma!ins*
The im-otance of ne!ati(e su!ical ma!ins fo localtumo contol an#8o su(i(al has %een #ocumente# foman. tumo t.-es& inclu#in! sacoma& %east cance&
-anceatic cance& an# ectal cance*
Thus it is clea that e(e. e=ot shoul# %e ma#e toachie(e micosco-icall. ne!ati(e su!ical ma!ins*
In"in! of the ma!ins& oientation of the s-ecimen %.the su!eon& an# imme#iate !oss e(aluation of thema!ins %. a -atholo!ist usin! fo?en'section anal.sis$hen necessa. ma. assist in achie(in! ne!ati(ema!ins at the ,st o-eation*
7/23/2019 Onco Management
36/78
In the -ast it $as -esume# that the moea#ical the su!e.& the %ette theoncolo!ic outcome $oul# %e*
O(e the -ast 2 .eas& this has %een
eco!ni?e# as not necessail. %ein! tue&$hich has le# to moe conse(ati(eo-eations& $ith $i#e local e)cisionse-lacin! com-atmental esections of
sacomas& an# -atial mastectomies& s"in's-ain! mastectomies& an# %east'conse(in! thea-ies e-lacin! a#icalmastectomies fo %east cance*
7/23/2019 Onco Management
37/78
Unesecta%le cases ae
Patients in $hom the -ima.tumo is not esecta%le $ithne!ati(e su!ical ma!insae
consi#ee# to ha(e ino-ea%le#isease*
Disease in(ol(in! multi-le #istantmetastasesis #eeme# ino-ea%le%ecause it is usuall. not cua%le
$ith su!e. of the -ima.
7/23/2019 Onco Management
38/78
Su!ical Mana!ement of theRe!ional L.m-h No#e /asin
Most neo-lasms ha(e the a%ilit. to metastasi?e (ia thel.m-hatics*
Theefoe& most oncolo!ic o-eations ha(e %een #esi!ne#to emo(e the -ima. tumo an# #ainin! l.m-hatics en
%loc*
This t.-e of o-eati(e a--oach usuall. is un#eta"en$hen the l.m-h no#es #ainin! the -ima. tumo site liea#9acent to the tumo %e#& as is the case fo coloectal
cances an# !astic cances*
Fo tumos in $hich the e!ional l.m-h no#e %asin is notimme#iatel. a#9acent to the tumo 6e*!*& melanomas7&l.m-h no#e su!e. can %e -efome# thou!h a se-aate
incision*
7/23/2019 Onco Management
39/78
Fo most cances& in(ol(ement of thel.m-h no#es is one of the mostsi!ni,cant -o!nostic factos*
Inteestin!l.& emo(al of a la!enum%e of l.m-h no#es has %een foun#
to %e associate# $ith an im-o(e#o(eall su(ial ate fo man. tumos&inclu#in! %east cance& colon cance&an# lun! cance*
L.m-ha#enectom. is im-otant fosta!in! an# su(i(al*
7/23/2019 Onco Management
40/78
ill Ro!es e=ect
This -henomenon is& i#enti,cation of metastasesthat ha# fomel. %een silent an# uni#enti,e#lea#s to sta!e mi!ation an# thus to a -ecei(e#im-o(ement in chances of su(i(al*
Cleal. the im-act of l.m-ha#enectom. onsu(i(al $ill not %e easil. esol(e#*
/ecause minimi?in! e!ional ecuences as
much as -ossi%le is a !oal of cance teatment&the stan#a# of cae emains l.m-ha#enectom.fo most tumos*
h i i
7/23/2019 Onco Management
41/78
L.m-hatic ma--in!technolo!.A elati(el. ne$ #e(elo-ment in the su!ical
mana!ement of the clinicall. ne!ati(e e!ionall.m-h no#e %asin is the into#uction of l.m-haticma--in! technolo!.*
L.m-hatic ma--in! an# sentinel l.m-h no#e %io-s.$ee ,st e-ote# in 0JJ %. Ca%anas fo -enilecance*
No$& sentinel no#e %io-s. is the stan#a# of cae fothe mana!ement of melanoma an# %east cance*
Moeo(e& the utilit. of sentinel no#e %io-s. in othecance t.-es is %ein! e)-loe#*
7/23/2019 Onco Management
42/78
The ,st no#e to ecei(e #aina!e fom the tumo site is teme# thesentinel no#e*
This no#e is the no#e most li"el. to contain metastases& ifmetastases to that e!ional l.m-h no#e %asin ae -esent*
The !oal of l.m-hatic ma--in! an# sentinel l.m-h no#e %io-s. is toi#entif. an# emo(e the l.m-h no#e most li"el. to containmetastases in the least in(asi(e fashion*
The -actice of sentinel l.m-h no#e %io-s. follo$e# %. selecti(ee!ional l.m-h no#e #issection fo -atients $ith a -ositi(e sentinell.m-h no#e a(oi#s the mo%i#it. of l.m-h no#e #issections in-atients $ith ne!ati(e no#es*
An a##itional a#(anta!e of the sentinel l.m-h no#e techni:ue is thatit #iects attention to a sin!le no#e& $hich allo$s moe caefulanal.sis of the l.m-h no#e most li"el. to ha(e a -ositi(e .iel# an#inceases the accuac. of no#al sta!in!*
7/23/2019 Onco Management
43/78
7/23/2019 Onco Management
44/78
Poce#ue
L.m-hatic ma--in! is -efome# %. usin! isosulfan%lue #.e& technetium'la%ele# sulfu colloi# oal%umin& o a com%ination of %oth techni:ues to#etect sentinel no#es*
The com%ination of %lue #.e an# technetium has%een e-ote# to im-o(e the ca-a%ilit. of #etectin!sentinel l.m-h no#es*
The no#al #aina!e -atten usuall. is #etemine#$ith a -eo-eati(e l.m-hoscinti!am& an# the hotan#8o %lue no#es ae i#enti,e# $ith the assistanceof a !amma -o%e an# caeful no#al %asine)-loation*
7/23/2019 Onco Management
45/78
The no#es ae e(aluate# $ith seialsectionin!& hemato).lin an# eosin stainin!&
an# immunohistochemical anal.sis $ith S'0 -otein an# homato-inemeth.l%omi#e stainin! fo melanoma an#c.to"eatin stainin! fo %east cance*
Stu#ies also ae on!oin! to e(aluate theuse of molecula techni:ues such as RT'PCR to a-i#l. assess the sentinel no#e
status in the intao-eati(e settin!*
7/23/2019 Onco Management
46/78
S i l M t f
7/23/2019 Onco Management
47/78
Su!ical Mana!ement ofDistant Metastases
Patient selection is the "e. to the success of su!icalthea-. fo #istant metastases*
The cance t.-e is a ma9o #eteminant in su!ical
#ecision ma"in!*
A li(e metastasis fom a colon cance is moe li"el.to %e an isolate# an# thus esecta%le lesion than ali(e metastasis fom a -anceatic cacinoma*
In cuati(e su!e. fo #istant metastases& as $ithsu!e. fo -ima. tumos& the !oal is to esect themetastases $ith ne!ati(e ma!ins
7/23/2019 Onco Management
48/78
Chemothea-.In -atients $ith #ocumente# #istant metastatic #isease&
chemothea-. is usuall. the -ima. mo#alit. of thea-.*
The !oal of thea-. in this settin! is to #ecease the tumo%u#en& thus -olon!in! su(i(al*
Chemothea-. a#ministee# to a -atient $ho is at hi!h is" fo#istant ecuence %ut has no e(i#ence of #istant #isease isefee# to as adjuvant chemotherapy.
The !oal of a#9u(ant chemothea-. is ea#ication of micometastatic #isease& $ith the intent of #eceasin! ela-se ates
an# im-o(in! su(i(al ates*
A#9u(ant thea-. can %e a#ministee# afte su!e.6-osto-eati(e chemothea-.7 o %efoe su!e. 6-eo-eati(echemothea-.& neoa#9u(ant chemothea-.& o in#uctionthea-.7*
P ti
7/23/2019 Onco Management
49/78
Pe o-eati(echemothea-.
Peo-eati(e chemothea-. has thee -otential a#(anta!es*
The ,st is that -eo-eati(e e!ession of tumo canfacilitate esection of tumos that $ee initiall. ino-ea%leo allo$ moe conse(ati(e su!e. fo -atients $hosecance $as o-ea%le to %e!in $ith*
The secon# a#(anta!e of -eo-eati(e chemothea-. is theteatment of micometastases $ithout the #ela. of-osto-eati(e eco(e.*
The thi# a#(anta!e is the a%ilit. to assess a canceses-onse to teatment clinicall.&afte a num%e of cousesof chemothea-.& an# -atholo!icall.& afte su!icalesection* This is es-eciall. im-otant if altenati(eteatment e!imens ae a(aila%le to %e o=ee# to -atients$hose #isease es-on#e# ina#e:uatel.*
Tumou sensiti(it. to c.toto)ic
7/23/2019 Onco Management
50/78
. .chemothea-.
/ighly sensitivetumours$reasonable
prospect of cure
Moderatelysensitive tumours$palliation is the
main ob0ective
Relatively insensitivetumours$cytoto1ictherapy only indicated
in specialcircumstances or withtechniques of regionalinfusion
3o#!"ins #isease /east cance Cacinoma of lun! othe
than small'cell t.-e3i!h'!a#el.m-homas
Lo$'!a#el.m-homas
cacinomas of the hea#an# nec"
Testicula tumous Multi-le m.eloma Cacinoma of uteus an#ce(i)
Choiocacinoma Small'cell 6oat'cell7cacinoma of lun!
3e-atocellula cacinoma
ilms tumou Coloectal cance Renal a#enocacinoma
To)ic e=ects of
7/23/2019 Onco Management
51/78
To)ic e=ects ofchemothea-./one mao$ su--ession5 Causes anaemia&
thom%oc.to-enia an# leuco-enia 6-otentiall. fatal7
Immunosu--ession5Causes #iminishe# esistance too--otunistic infections
Nausea an# (omitin!5 Ten# to occu $ithin an hou ot$o of chemothea-.
Disu-tion of !astointestinal e-ithelial tuno(e5Causes #iahoea an# oal ulceation
To)icit. to hai follicles5 Paticulal. eto-osi#e&c.clo-hos-hami#e an# #o)ou%icin*Causes hai loss
Gona#al in9u.5 Loss of li%i#o& steilit. an# -ossi%le
muta!enesisRa-i# tumou #estuction on a massi(e scale5 Lea#s
to elease of -uines an# -.imi#ines 6onl. a -o%lemin leu"aemias an# l.m-homas7 $hich causeh.-euicaemia& -esentin! as o%stucti(e uo-ath.
an# enal failue*
7/23/2019 Onco Management
52/78
3omonal Thea-.
Some tumos& most nota%l. %east an# -ostate cances&oi!inate fom tissues $hose !o$th is un#e homonal contol*
3omonal anticance a!ents inclu#e an#o!ens& antian#o!ens&antiesto!ens& esto!ens& !lucocoticoi#s& !ona#oto-ininhi%itos& -o!estins& aomatase inhi%itos& an# somatostatin
analo!ues*
3omones o homone'li"e a!ents can %e a#ministee# to inhi%ittumo !o$th %. %loc"in! o anta!oni?in! the natuall. occuin!su%stance& such as $ith the esto!en anta!onist tamo)ifen*
3omonal thea-. -o(i#es a hi!hl. tumo's-eci,c fom ofthea-. in sensiti(e tissues*
In %east cance& esto!en an# -o!esteone ece-to status isuse# to -e#ict the success of homonal thea-.*
7/23/2019 Onco Management
53/78
Ta!ete# thea-.
The %asic -inci-le of molecula thea-eutics is to e)-loitthe molecula #i=eences %et$een nomal cells an# cancecells to #e(elo- ta!ete# thea-ies*
Thus ta!ete# thea-ies usuall. ae #iecte# at the-ocesses in(ol(e# in tumo !o$th athe than #iectl.ta!etin! the tumo cells*
The i#eal molecula ta!et $oul# %e e)clusi(el. e)-esse#in the cance cells& %e the #i(in! foce of the -olifeationof the cance cells& an# %e citical to thei su(i(al*
The ma9o !ou-s of ta!ete# thea-. a!ents ae inhi%itosof !o$th facto ece-tos& inhi%itos of intacellula si!naltans#uction& cell'c.cle inhi%itos& a-o-tosis'%ase#thea-ies& an# antian!io!enic com-oun#s*
7/23/2019 Onco Management
54/78
Ta!ete# Thea-ies
Generic 2ame Target 3nitial 3ndication
Tastu?uma% 3e 2 /east cance
La-atini% 3e 2 1 EGFR /east cance
Cetu)ima% EGFR Coloectal cance
/e(aci?uma% +EGF Coloectal cance
Soafeni% +EGFR&PDGFR Renal cellcacinoma
Temsiolimus mTOR Renal cellcacinoma
Imatini% C'"it & %c'a%l &PDGFR
GIST 1 CML
Sunitini% C'"it & PDGFR &+EGFR
CML
7/23/2019 Onco Management
55/78
Immunothea-.
The aim of immunothea-. is to in#uce o -otentiateinheent antitumo immunit. that can #esto.cance cells*
Cental to the -ocess of antitumo immunit. is the
a%ilit. of the immune s.stem to eco!ni?e tumo'associate# anti!ens -esent on human cances an#to #iect c.toto)ic es-onses thou!h humoal o T'cellme#iate# immunit.*
O(eall&T'cellme#iate# immunit. a--eas to ha(ethe !eate -otential of the t$o fo ea#icatin!tumo cells* T cells eco!ni?e anti!ens on thesufaces of ta!et cells as small -e-ti#es -esente#%. class I an# class II M3C molecules*
7/23/2019 Onco Management
56/78
Tumou (accines
The eal. attem-ts at (accination a!ainst cances use#allo!eneic cultue# cance cells& inclu#in! ia#iate#cells& cell l.sates& an# she# anti!ens isolate# fom tissuecultue su-enatants*
An altenate state!. is the use of autolo!ous tumo(accines*
Tissue s-eci,cit. an# immuno!enicit. ae im-otant#eteminants in choosin! an a--o-iate ta!et*
+accines #iecte# at #e,ne# tumo anti!ens aim tocom%ine selecte# tumo anti!ens an# a--o-iate outesfo #eli(ein! these anti!ens to the immune s.stem too-timi?e antitumo immunit.*
7/23/2019 Onco Management
57/78
Limitations
Toleanceto self'anti!ens e)-esse# in tumosis a limitation in !eneatin! antitumoes-onses*
Recentl.& se(eal -ath$a.s that mo#ulatetoleance an# a--oaches to mani-ulatin!these -ath$a.s ha(e %een i#enti,e#5
-ath$a.s that acti(ate -ofessional anti!en'-esentin! cells such as Toll'li"e ece-tos&
!o$th factos& an# the CDK -ath$a.Hc.to"ines to enhance immunoacti(ationH an#-ath$a.s that inhi%it T'cell inhi%ito. si!nals o
Te!s*
7/23/2019 Onco Management
58/78
A#(ancements *
A ne$ state!. %ein! acti(el. e)-loe# in(ol(es the useof c.toto)ic T'l.m-hoc.te anti!en K 6CTLA'K7*
CTLA'K e)ists on the sufaces of T cells an# has ahomeostatic immunosu--essi(e function&
#o$ne!ulatin! the es-onse of T cells to stimuli*
T$o full. human monoclonal anti'CTLA'K anti%o#ies&i-ilimuma% an# temelimuma%& ae in clinical#e(elo-ment*
Anti'CTLA'K anti%o#ies ae un#e stu#. fo use inmelanoma as $ell as se(eal othe cance t.-es assin!le a!ents& in com%ination $ith inteleu"in'2&chemothea-.& o -e-ti#e (accines*
7/23/2019 Onco Management
59/78
7/23/2019 Onco Management
60/78
7/23/2019 Onco Management
61/78
One of the -omisin! a--oaches to incease thenum%e of tumo cells tans#uce# is the use of a
e-lication'com-etent (iussuch as a -a(o(ius&human eo(ius& o (esicula stomatitis (ius thatselecti(el. e-licates $ithin mali!nant cells an#l.ses them moe e@cientl. than it #oes nomal cells*
Anothe state!. fo "illin! tumo cells $ith suici#e!enes e)-loits tumo's-eci,c e)-ession elements&such as the MUC'0& PSA& CEA& o +EGF -omotes&that can %e use# to achie(e tissue's-eci,c o tumo's-eci,c e)-ession of the #esie# !ene*
/ecause the !oal in cance thea-. is to ea#icates.stemic #isease& o-timi?ation of #eli(e. s.stems isthe "e. to success fo !ene thea-. state!ies*
7/23/2019 Onco Management
62/78
Ra#iothea-.
A%so-tion of a#iation %. the ta!ettissue causes hi!hl. eacti(e feea#icals to a--ea $hich #ama!eDNA an# cause cell #eath at mitosis*
ith thei hi!h ate of -olifeation&cance cells ae -aticulal. sensiti(e&
%ut nomal tissues $ith a hi!h ate ofcell tuno(e 6e*!* !ut mucosa an#%one mao$7 ae also (ulnea%le*
Ra#iation can %e #iecte# to a
7/23/2019 Onco Management
63/78
Ra#iation can %e #iecte# to atumou in thee $a.s5
E1ternal beam irradiation'this is the metho# mostcommonl. em-lo.e# fo s"in lesions an# #ee-l. locate#tumous
4ocal application of radioisotopes 5brachytherapy6' thisin(ol(es -lacin! the a#iation souce u-on o $ithin the tissue
to %e ia#iate#*#laquesouces of a#iation can %e em-lo.e# fo s"in
mali!nancies
Ra#ioacti(e iridium wires or caesium needlescan %eim-lante# in the oal ca(it.& -ostate& s"in an# sometimes%east& !i(in! hi!h'#ose local ia#iation*
Im-lantation is usuall. -efome# un#e !eneal anaesthesia*
Fo cance of the uteus an# ce(i)& the a#ioacti(e souce is-lace# in a seale# containe $ithin the uteine o (a!inalca(it.H it can %e insete# $ithout is" to sta= (ia a
7/23/2019 Onco Management
64/78
#metho# 5
Systemic radioisotope therapy'a#ioacti(eio#ine !i(en %. mouth o inta(enousl. is a$ell'esta%lishe# teatment fo th.oto)icosisan# can also %e use# fo teatin! $ell'#i=eentiate# th.oi# tumous -o(i#e# theest of the th.oi# has %een emo(e#& e(en ife)tensi(e metastases ae -esent*
Attem-ts ae still %ein! ma#e to #iect
a#ioisoto-es -ecisel. to cance cells %.attachin! them to tumou's-eci,c monoclonal
anti%o#ies*
Ra#iosensiti(e o esistant
7/23/2019 Onco Management
65/78
Ra#iosensiti(e o esistant
3i!hl. a#iosensiti(e
Ma9o a--lications of
7/23/2019 Onco Management
66/78
Ma9o a--lications ofa#iothea-.
Ra#iothea-. has thee ma9oa--lications in cance teatment5
as a -ima. cue&
as a#9u(ant teatment to su!e.6an#8o chemothea-.7 o
as -alliation*
Pima. cuati(e
7/23/2019 Onco Management
67/78
.a#iothea-.Ra#iothea-. $ith cuati(e intent is "no$n as radicalradiotherapy& an# is $i#el. use# fo %asal cell an#
s:uamous cell cacinomas of the s"in*
It is also use# fo cetain tumous $hich ae technicall.#i@cult to emo(e o $hee su!e. $oul# %e -aticulal.mutilatin!& as in the hea#& nec" an# la.n)*
Ra#iothea-. can %e #iecte# at the -ima. lesion an#e!ional l.m-h no#es if a--o-iate an# ates of cue aecom-aa%le to those achie(e# %. su!ical e)cision*
Ra#iothea-. is em-lo.e# in the teatment of most
common soli# tumous an# in eal. cases of 3o#!"in an#non'3o#!"in l.m-homas*
Ra#iothea-. can also achie(e cue in u- to of %la##ecances& $ith sal(a!e c.stectom. ese(e# fo ecuence*
7/23/2019 Onco Management
68/78
A#9u(ant a#iothea-.The -inci-le un#el.in! ad0uvant therapy& $hethe a#iolo!ical& chemical o
homonal& is that clinicall. un#etecta%le micometastases ae often -esent intissue suoun#in! a -ima. lesion& in e!ional no#es an# in emote locations*
These ae %elie(e# to %e es-onsi%le fo local& e!ional an# s.stemic ecuenceafte a -ima. lesion has a--aentl. %een com-letel. emo(e#*
A#9u(ant a#iothea-. can %e a--lie# to local tissue an# e!ional no#es %efoesu!e. 6"no$n as neoad0uvant therapy7& afte su!e. o %oth& to t. toeliminate micometastases*
A#9u(ant a#iothea-. is $i#el. em-lo.e# fo cance of the %east afteemo(in! the -ima. lesion locall. o %. mastectom.* If a)illa. no#es aein(ol(e#& a#iothea-. can %e an altenati(e to a#ical l.m-h no#e cleaance*
Ra#iothea-. is also hi!hl. e=ecti(e a#9u(ant thea-. in seminoma of the testis*
In cetain cances& teatment a shot time %efoe su!e. $ith eithea#iothea-. o chemothea-. o %oth can %in! %ene,ts* This ma. enhance thecue ate fo su!e. o it ma. %e use# to #o$nsi?e a cance to ma"e su!e.-actica%le& e*!* in locall. a#(ance# ectal cance*
7/23/2019 Onco Management
69/78
Palliati(e a#iothea-.
Palliati(e a#iothea-. is em-lo.e# fo local contol of -ima. ometastatic lesions $ith the intention of teatin! s.m-toms an#causin! the minimum of si#e e=ects*
It is also em-lo.e# to -e(ent im-en#in! com-lications& e*!* s-inalco# com-ession*
Much lo$e total #oses ae use# fo -alliation than fo attem-ts atcueH shot couses o single high$dose fractionsae usuall.a#e:uate an# ae tolea%le an# con(enient fo the -atient*
Ra#iothea-. is -aticulal. e=ecti(e in contollin! metastatic
#e-osits in %one an# %ain*
The -ain of %one metastases can often %e com-letel. elie(e# %.a#iothea-.& as can some of the neuolo!ical manifestations of%ain secon#aies*
7/23/2019 Onco Management
70/78
Com-lications of RT
Systemic side e7ectsMalaise an# fati!ue'(e.common
E7ects occurring in irradiated tissues
S"in 6es-eciall. a)illa& !oin an# -eineum7 5 Re#ness&itchin! an# mil# -ain* S"in %ea"#o$n
A%#omen an# -el(is 5 Nausea& (omitin!& #iahoeaFe:uenc.& #.suia& haematuia 6a#iation c.stitis7
D. mouth 6)eostomia7 #ue to sali(a. !lan# in9u.
Painful mouth& #.s-ha!ia an# altee# taste* This is #ueto in
7/23/2019 Onco Management
71/78
Ra#iation in#uce# cances
Types of e1posure Type of cancerNec" ia#ition #uin! chilhoo# Th.oi# cacinoma
Ra#iation thea-. fo othemali!nant tumous
Th.oi#&%east&!astic&lun!cances*Melanoma
Canial ia#iation CNS tumous/east ia#iation fo -ost-atum mastitis
/east cances
/ush lic"in! %. a#ium #ial-aintes
/one sacomas
Uanium e)-osue Lun! cancesInuteo e)-osue leu"emia
Pe(ention An ounce of -e(ention
7/23/2019 Onco Management
72/78
Pe(ention ' An ounce of -e(entionis $oth a -oun# of cue
Cance -e(ention can %e #i(i#e# intothee cate!oies5
6a7 -ima. -e(ention 6i*e*& -e(ention
of initial cances in health. in#i(i#uals7&6%7 secon#a. -e(ention 6i*e*&
-e(ention of cance in in#i(i#uals $ith-emali!nant con#itions7& an#
6c7 tetia. -e(ention 6i*e*& -e(entionof secon# -ima. cances in -atientscue# of thei initial #isease7*
7/23/2019 Onco Management
73/78
chemo-e(ention
The s.stemic o local a#ministation of thea-eutica!ents to -e(ent the #e(elo-ment of cance& calle#chemo-e(ention*
E) 0 5 tamo)ifen a#ministation e#uces the is" of
%east cance %. one half an# e#uces the is" ofesto!en ece-to-ositi(e tumos %. in hi!h'is" -atients*
E) 2 5 Celeco)i% has %een sho$n to e#uce -ol.-num%e an# -ol.- %u#en in -atients $ith familial
a#enomatous -ol.-osis 6FAP7E) 5 In hea# an# nec" cance& 0'cis'etinoic aci#
has %een sho$n %oth to e(ese oal leu"o-la"ia an#to e#uce secon# -ima. tumo #e(elo-ment*
7/23/2019 Onco Management
74/78
Recent
a#(ance
s
Ten#s an# E(ol(in! Technolo!ies
7/23/2019 Onco Management
75/78
in Oncolo!. ' Cance Sceenin! an#Dia!nosis
Mati)'assiste# lase #eso-tionioni?ation time'of'
7/23/2019 Onco Management
76/78
Ten#s an# E(ol(in! Technolo!ies inOncolo!. su!ical thea-.
The cuent ten# in su!e. is to$a# moeconse(ati(e esections*
ith ealie i#enti,cation of tumos& moeconse(ati(e su!eies ma. %e -ossi%le* The
!oal& ho$e(e& is al$a.s to emo(e the tumo en%loc $ith $i#e ne!ati(e ma!ins*
Anothe inteestin! aea %ein! e)-loe# is the
#estuction of tumos %. techni:ues such asa#iofe:uenc. a%lation& c.oa%lation& an# heat'-o#ucin! technolo!ies li"e lases& mico$a(es&o focuse# ultasoun#*
7/23/2019 Onco Management
77/78
T3AN; YOU
##i i i #
7/23/2019 Onco Management
78/78
A##itions e:uie#
Nanotechnolo!.Ro%otics
In su!ical oncolo!.